Pharmacology and rationale for imatinib in the treatment of scleroderma

References

• GabrielliAAvvedimentoEVKriegTSclerodermaN Engl J Med2009360191989200319420368
   PubMed Web of Science ®Google Scholar
• AlamanosYTsifetakiNVoulgariPVEpidemiology of systemic sclerosis in northwest Greece 1981 to 2002Semin Arthritis Rheum200534571472015846586
   PubMed Web of Science ®Google Scholar
• AllcockRJForrestICorrisPACrookPRGriffithsIDA study of the prevalence of systemic sclerosis in northeast EnglandRheumatology (Oxford)200443559660214872101
   PubMed Web of Science ®Google Scholar
• Arias-NunezMCLlorcaJVazquez-RodriguezTRSystemic sclerosis in northwestern Spain: a 19-year epidemiologic studyMedicine (Baltimore)200887527228018794710
   PubMed Web of Science ®Google Scholar
• Lo MonacoABruschiMLa CorteRVolpinariSTrottaFEpidemiology of systemic sclerosis in a district of northern ItalyClin Exp Rheumatol2011292 Suppl 65S10S1421586212
   PubMed Web of Science ®Google Scholar
• MayesMDScleroderma epidemiologyRheum Dis Clin North Am200329223925412841293
   PubMed Web of Science ®Google Scholar
• MedsgerTAJrEpidemiology of systemic sclerosisClin Dermatol19941222072168076257
   PubMed Web of Science ®Google Scholar
• SilmanAJanniniSSymmonsDBaconPAn epidemiological study of scleroderma in the West MidlandsBr J Rheumatol19882742862903261609
   PubMedGoogle Scholar
• SilmanAJEpidemiology of sclerodermaAnn Rheum Dis199150Suppl 48468531750796
   PubMed Web of Science ®Google Scholar
• SteenVDMedsgerTAJrEpidemiology and natural history of systemic sclerosisRheum Dis Clin North Am19901611102406801
   PubMed Web of Science ®Google Scholar
• TamakiTMoriSTakeharaKEpidemiological study of patients with systemic sclerosis in TokyoArch Dermatol Res199128363663711796818
   PubMed Web of Science ®Google Scholar
• Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria CommitteePreliminary criteria for the classification of systemic sclerosis (scleroderma)Arthritis Rheum19802355815907378088
   PubMed Web of Science ®Google Scholar
• LeRoyECBlackCFleischmajerRScleroderma (systemic sclerosis): classification, subsets and pathogenesisJ Rheumatol19881522022053361530
   PubMed Web of Science ®Google Scholar
• HunzelmannNKriegTThe German Network for Systemic Sclerosis (DNSS): current data on diagnostics and therapyHautarzt201263Suppl 17175 German22543950
   PubMedGoogle Scholar
• HunzelmannNGenthEKriegTThe registry of the German Network for Systemic Scleroderma: frequency of disease subsets and patterns of organ involvementRheumatology (Oxford)20084781185119218515867
   PubMed Web of Science ®Google Scholar
• MoinzadehPFehrADammBKriegTHunzelmannNThe German Network for Systemic SclerodermaHautarzt20075810858863 German17846731
   PubMed Web of Science ®Google Scholar
• BennettRMScleroderma overlap syndromesRheum Dis Clin North Am19901611851982406807
   PubMed Web of Science ®Google Scholar
• PakozdiANihtyanovaSMoinzadehPOngVHBlackCMDentonCPClinical and serological hallmarks of systemic sclerosis overlap syndromesJ Rheumatol201138112406240921844148
   PubMed Web of Science ®Google Scholar
• MoinzadehPDentonCPAbrahamDBiomarkers for skin involvement and fibrotic activity in sclerodermaJ Eur Acad Dermatol Venereol201226326727621819452
   PubMed Web of Science ®Google Scholar
• ReinerJEDattaPKTGF-beta-dependent and -independent roles of STRAP in cancerFront Biosci201116105115
   Web of Science ®Google Scholar
• DanielsCEWilkesMCEdensMImatinib mesylate inhibits the profibrogenic activity of TGF-beta and prevents bleomycin-mediated lung fibrosisJ Clin Invest200411491308131615520863
   PubMed Web of Science ®Google Scholar
• CromackDTPierceGFMustoeTATGF-beta and PDGF mediated tissue repair: identifying mechanisms of action using impaired and normal models of wound healingProg Clin Biol Res19913653593731862144
   PubMedGoogle Scholar
• ten FreyhausHDumitrescuDBovenschulteHErdmannERosenkranzSSignificant improvement of right ventricular function by imatinib mesylate in scleroderma-associated pulmonary arterial hypertensionClin Res Cardiol200998426526719219392
   PubMed Web of Science ®Google Scholar
• SaggarRLynchJPBelperioJAPulmonary arterial hypertension and lung transplantationSemin Respir Crit Care Med201031214716020354928
   PubMed Web of Science ®Google Scholar
• PullamsettiSSBerghausenEMDabralSRole of Src tyrosine kinases in experimental pulmonary hypertensionArterioscler Thromb Vasc Biol20123261354136522516066
   PubMed Web of Science ®Google Scholar
• BuchdungerEZimmermannJMettHInhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivativeCancer Res19965611001048548747
   PubMed Web of Science ®Google Scholar
• DrukerBJTamuraSBuchdungerEEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cellsNat Med1996255615668616716
   PubMed Web of Science ®Google Scholar
• RobinsonDRWuYMLinSFThe protein tyrosine kinase family of the human genomeOncogene200019495548555711114734
   PubMed Web of Science ®Google Scholar
• DrukerBJTalpazMRestaDJEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaN Engl J Med2001344141031103711287972
   PubMed Web of Science ®Google Scholar
• MesaRASteensmaDPHoyerJKetterlingRPConcomitant myelodysplastic syndrome and chronic myeloid leukaemia: treatment outcomes with imatinib mesylateBr J Haematol2003123236636714531922
   PubMed Web of Science ®Google Scholar
• AntoniuSAImatinib mesylate for the treatment of hypereosinophilic syndromesCurr Opin Investig Drugs2006711980984
   Google Scholar
• CoutreSGotlibJTargeted treatment of hypereosinophilic syndromes and chronic eosinophilic leukemias with imatinib mesylateSemin Cancer Biol200414430731515305431
   PubMed Web of Science ®Google Scholar
• BlankeCDEisenbergBLHeinrichMCGastrointestinal stromal tumorsCurr Treat Options Oncol20012648549112057094
   PubMedGoogle Scholar
• van OosteromATJudsonIVerweijJSafety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyLancet200135892911421142311705489
   PubMed Web of Science ®Google Scholar
• DalalBIHorsmanDEBruyereHForrestDLImatinib mesylate responsiveness in aggressive systemic mastocytosis: novel association with a platelet derived growth factor receptor beta mutationAm J Hematol2007821777917133421
   PubMed Web of Science ®Google Scholar
• Johnson-JahangirHShermanWRatnerDUsing imatinib as neoadjuvant therapy in dermatofibrosarcoma protuberans: potential pluses and minusesJ Natl Compr Canc Netw20108888188520870634
   PubMed Web of Science ®Google Scholar
• DrukerBJImatinib mesylate in the treatment of chronic myeloid leukaemiaExpert Opin Pharmacother20034696397112783592
   PubMed Web of Science ®Google Scholar
• van ErpNPGelderblomHGuchelaarHJClinical pharmacokinetics of tyrosine kinase inhibitorsCancer Treat Rev200935869270619733976
   PubMed Web of Science ®Google Scholar
• SparanoBAEgorinMJPariseRAEffect of antacid on imatinib absorptionCancer Chemother Pharmacol200963352552818500518
   PubMed Web of Science ®Google Scholar
• PetainAKattygnarathDAzardJPopulation pharmacokinetics and pharmacogenetics of imatinib in children and adultsClin Cancer Res200814217102710918981009
   PubMed Web of Science ®Google Scholar
• DelbaldoCChatelutEReMPharmacokinetic-pharmacodynamic relationships of imatinib and its main metabolite in patients with advanced gastrointestinal stromal tumorsClin Cancer Res20061220 Pt 16073607817062683
   PubMed Web of Science ®Google Scholar
• BoddyAVSluddenJGriffinMJPharmacokinetic investigation of imatinib using accelerator mass spectrometry in patients with chronic myeloid leukemiaClin Cancer Res200713144164416917634544
   PubMed Web of Science ®Google Scholar
• OkudaKWeisbergEGillilandDGGriffinJDARG tyrosine kinase activity is inhibited by STI571Blood20019782440244811290609
   PubMed Web of Science ®Google Scholar
• BuchdungerECioffiCLLawNAbl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptorsJ Pharmacol Exp Ther2000295113914510991971
   PubMed Web of Science ®Google Scholar
• HeinrichMCGriffithDJDrukerBJWaitCLOttKAZiglerAJInhibition of c-kit receptor tyrosine kinase activity by STI571, a selective tyrosine kinase inhibitorBlood200096392593210910906
   PubMed Web of Science ®Google Scholar
• AnXTiwariAKSunYDingPRAshbyCRJrChenZSBCR-ABL tyrosine kinase inhibitors in the treatment of Philadelphia chromosome positive chronic myeloid leukemia: a reviewLeuk Res201034101255126820537386
   PubMed Web of Science ®Google Scholar
• DistlerJHDistlerOIntracellular tyrosine kinases as novel targets for anti-fibrotic therapy in systemic sclerosisRheumatology (Oxford)200847Suppl 5v10v1118784126
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienSGFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med2006355232408241717151364
   PubMed Web of Science ®Google Scholar
• KerkelaRGrazetteLYacobiRCardiotoxicity of the cancer therapeutic agent imatinib mesylateNat Med200612890891616862153
   PubMed Web of Science ®Google Scholar
• AtallahEDurandJBKantarjianHCortesJCongestive heart failure is a rare event in patients receiving imatinib therapyBlood200711041233123717449798
   PubMed Web of Science ®Google Scholar
• BarstRJPDGF signaling in pulmonary arterial hypertensionJ Clin Invest2005115102691269416200204
   PubMed Web of Science ®Google Scholar
• BhattacharyyaSIshidaWWuMA non-Smad mechanism of fibroblast activation by transforming growth factor-beta via c-Abl and Egr-1: selective modulation by imatinib mesylateOncogene200928101285129719151753
   PubMed Web of Science ®Google Scholar
• PannuJAsanoYNakerakantiSSmad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylateArthritis Rheum20085882528253718668566
   PubMed Web of Science ®Google Scholar
• DistlerJHJungelAHuberLCImatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosisArthritis Rheum200756131132217195235
   PubMed Web of Science ®Google Scholar
• HinchcliffMHuangCCIshidaWImatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitroClin Exp Rheumatol2012302 Suppl 71S86S9622691216
   PubMed Web of Science ®Google Scholar
• SoriaACario-AndreMLepreuxSThe effect of imatinib (Glivec) on scleroderma and normal dermal fibroblasts: a preclinical studyDermatology2008216210911718216472
   PubMed Web of Science ®Google Scholar
• FurspanPBChatterjeeSFreedmanRRIncreased tyrosine phosphorylation mediates the cooling-induced contraction and increased vascular reactivity of Raynaud’s diseaseArthritis Rheum20045051578158515146428
   PubMed Web of Science ®Google Scholar
• AkhmetshinaAVenalisPDeesCTreatment with imatinib prevents fibrosis in different preclinical models of systemic sclerosis and induces regression of established fibrosisArthritis Rheum200960121922419116940
   PubMed Web of Science ®Google Scholar
• AonoYNishiokaYInayamaMImatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in miceAm J Respir Crit Care Med2005171111279128515735062
   PubMed Web of Science ®Google Scholar
• LiMAbdollahiAGroneHJLipsonKEBelkaCHuberPELate treatment with imatinib mesylate ameliorates radiation-induced lung fibrosis in a mouse modelRadiat Oncol200946620025728
   PubMed Web of Science ®Google Scholar
• PapadakisVKarakasisDSfikakisPPIs imatinib mesylate a promising drug in scleroderma due to extensive chronic graft-versus-host disease?Leuk Lymphoma200950347147419253137
   PubMed Web of Science ®Google Scholar
• MagroLCatteauBCoiteuxVBrunoBJouetJPYakoub-AghaIEfficacy of imatinib mesylate in the treatment of refractory sclerodermatous chronic GVHDBone Marrow Transplant2008421175776018762765
   PubMed Web of Science ®Google Scholar
• OlivieriJColuzziSAttolicoIOlivieriATirosin kinase inhibitors in chronic graft versus host disease: from bench to bedsideScientific World Journal2011111908193122125447
   PubMed Web of Science ®Google Scholar
• BibiYGottliebABA potential role for imatinib and other small molecule tyrosine kinase inhibitors in the treatment of systemic and localized sclerosisJ Am Acad Dermatol200859465465818571768
   PubMed Web of Science ®Google Scholar
• ElmholdtTRBuusNHRamsingMOlesenABAntifibrotic effect after low-dose imatinib mesylate treatment in patients with nephrogenic systemic fibrosis: an open-label non-randomized, uncontrolled clinical trialJ Eur Acad Dermatol Venereol12202011 Epub ahead of print
   Web of Science ®Google Scholar
• KayJHighWAImatinib mesylate treatment of nephrogenic systemic fibrosisArthritis Rheum20085882543254818668587
   PubMedGoogle Scholar
• SfikakisPPGorgoulisVGKatsiariCGEvangelouKKostopoulosCBlackCMImatinib for the treatment of refractory, diffuse systemic sclerosisRheumatology (Oxford)200847573573718326532
   PubMed Web of Science ®Google Scholar
• van DaelePLDikWAThioHBIs imatinib mesylate a promising drug in systemic sclerosis?Arthritis Rheum20085882549255218668570
   PubMedGoogle Scholar
• GuoLChenXXGuYYZouHJYeSLow-dose imatinib in the treatment of severe systemic sclerosis: a case series of six Chinese patients and literature reviewClin Rheumatol20123191395140022875698
   PubMed Web of Science ®Google Scholar
• PopeJMcBainDPetrlichLImatinib in active diffuse cutaneous systemic sclerosis: results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single centerArthritis Rheum201163113547355121769850
   PubMed Web of Science ®Google Scholar
• TamakiZAsanoYHatanoMEfficacy of low-dose imatinib mesylate for cutaneous involvement in systemic sclerosis: a preliminary report of three casesMod Rheumatol2012221949921633912
   PubMed Web of Science ®Google Scholar
• FiettaABardoniASalviniRAnalysis of bronchoalveolar lavage fluid proteome from systemic sclerosis patients with or without functional, clinical and radiological signs of lung fibrosisArthritis Res Ther200686R16017044913
   PubMed Web of Science ®Google Scholar
• AzumaMNishiokaYAonoYRole of alpha1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in miceAm J Respir Crit Care Med2007176121243125017717205
   PubMed Web of Science ®Google Scholar
• HatanoMYaoAShigaTKinugawaKHirataYNagaiRImatinib mesylate has the potential to exert its efficacy by down-regulating the plasma concentration of platelet-derived growth factor in patients with pulmonary arterial hypertensionInt Heart J201051427227620716845
   PubMed Web of Science ®Google Scholar
• KhannaDSaggarRMayesMDA one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung diseaseArthritis Rheum201163113540354621769849
   PubMed Web of Science ®Google Scholar
• SpieraRFGordonJKMerstenJNImatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trialAnn Rheum Dis20117061003100921398330
   PubMed Web of Science ®Google Scholar
• BourniaVKEvangelouKSfikakisPPTherapeutic inhibition of tyrosine kinases in systemic sclerosis: a review of published experience on the first 108 patients treated with imatinibSemin Arthritis Rheum7102012 Epub ahead of print
   Web of Science ®Google Scholar
• ChungLRuizPWoodTEvaluation of an imatinib response gene signature in patients with systemic sclerosisArthritis Rheum201062S239
   Google Scholar
• SabnaniIZuckerMJRosensteinEDA novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamideRheumatology (Oxford)2009481495218815156
   PubMed Web of Science ®Google Scholar
• PreySEzzedineKDoussauAImatinib mesylate in scleroderma-associated diffuse skin fibrosis: a phase II multicentre randomized double-blinded controlled trialBr J Dermatol201216751138114423039171
   PubMed Web of Science ®Google Scholar
• BeyerCDistlerJHDistlerOAre tyrosine kinase inhibitors promising for the treatment of systemic sclerosis and other fibrotic diseases?Swiss Med Wkly2010140w1305020419513
   PubMed Web of Science ®Google Scholar
• OhnishiKSakaiFKudohSOhnoRTwenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylateLeukemia20062061162116416598305
   PubMed Web of Science ®Google Scholar
• BeyerCDistlerJHTyrosine kinase signaling in fibrotic disorders: translation of basic research to human diseaseBiochim Biophys Acta6192012 Epub ahead of print
   Web of Science ®Google Scholar